Gearing up new partnerships, Boehringer gets an option to buy a new player in oncolytic viruses in $230M deal
Boehringer Ingelheim is actively joining the hunt for the next big oncolytic virus program in the hot and happening cancer field.
After backing a small startup round for ViraTherapeutics a little more than a year ago, the pharma company has come back with a $230 million package deal to partner on their work — grabbing an option in the process to buy the company. And the pharma giant says the partnership is a sign of more deals to come as it gears up new pacts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.